Intellia Therapeutics (NTLA) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Intellia Therapeutics (NTLA) PT Lowered to $50 at Truist Securities
March 3, 2025 11:55 AM ESTTruist Securities analyst Joon Lee lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $50.00 (from $90.00) while maintaining a Buy rating.
The analyst comments "4Q24: Restructuring underway should help extend operational runway into 1H27 as NTLA-2002 is poised to be the historic first in... More
